WARRINGTON, Pa., Dec. 1,
2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq:
WINT), a biotechnology company focused on developing aerosolized
KL4 surfactant therapies for respiratory diseases, today announced
that two abstracts have been accepted for presentation at the Hot
Topics in Neonatology conference being held December 5 – 7, 2016 in Washington, DC. For over 30 years, Hot
Topics has been a premiere neonatal conference, with more than 1000
neonatologists and perinatologists from around the world attending
each year.
Summarized below are the abstract titles and presentation
times. The Hot Topics in Neonatology posters are embargoed
until presentation time, but once presented, will be available on
the Windtree Therapeutics website – www.windtreetx.com.
Timothy J. Gregory, Ph.D., Senior
Director, Clinical and Pre-Clinical Science, at Windtree will
present Deposition of Aerosolized Lucinactant in
Non-Human Primates from 5:45 pm to 6:45 pm on December 5, 2016.
Paul M Shore, M.D., M.S., Senior Director, Clinical Research, at
Windtree will present Wide Variation in Rate and Timing of
Endotracheal Intubation (ETI) in Preterm Neonates with Respiratory
Distress Syndrome (RDS) from 5:45 pm
to 6:45 pm on December 5,
2016.
Windtree's lead product candidate is AEROSURF® (lucinactant for
inhalation), a novel, investigational combination drug/device
product that combines the Company's proprietary KL4 surfactant and
aerosolization technologies. AEROSURF is being developed to
potentially reduce or eliminate the need for endotracheal
intubation and mechanical ventilation in the treatment of premature
infants with RDS. Enrollment is ongoing in a phase 2b clinical
trial to study AEROSURF administered to premature infants 29 to 32
week GA receiving nasal continuous positive airway pressure (nCPAP)
for RDS, compared to infants receiving nCPAP alone.
About Windtree Therapeutics
Windtree Therapeutics,
Inc. is a clinical-stage biotechnology company focused on
developing novel surfactant therapies for respiratory diseases
and other potential applications. Windtree's proprietary technology
platform includes a synthetic, peptide-containing surfactant (KL4
surfactant) that is structurally similar to endogenous pulmonary
surfactant and novel drug-delivery technologies being developed to
enable noninvasive administration of aerosolized KL4
surfactant. Windtree is focused initially on improving the
management of respiratory distress syndrome (RDS) in premature
infants and believes that its proprietary technology may make it
possible, over time, to develop a pipeline of KL4 surfactant
product candidates to address a variety of respiratory diseases for
which there are few or no approved therapies.
For more information, please visit the Company's website
at www.windtreetx.com.
Logo - http://photos.prnewswire.com/prnh/20160415/356055LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/windtree-therapeutics-announces-upcoming-presentations-at-hot-topics-in-neonatology-300371328.html
SOURCE Windtree Therapeutics, Inc.